Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16690141 | 0.89 | CES1 (0.56) | CES1CES2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL267756 | 0.87 | CES1 (0.54) | CES1CES2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL267729 | 0.86 | CES1 (0.52) | CES1CES2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13192526 | 0.85 | XDH (0.47) | CES1CES2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL267670 | 0.85 | CES1 (0.51) | CES1CES2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9962620 | 0.81 | SMN1; SMN2 (0.42) | CES1CES2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL12328537 | 0.79 | CES2 (0.50) | CES1CES2SMN1; SMN2RAB9AMAPK1 | |
| SCHEMBL16690144 | 0.79 | CES2 (0.48) | CES1CES2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9897113 | 0.79 | CES2 (0.50) | CES1CES2SMN1; SMN2RAB9AMAPK1 | |
| SCHEMBL9897115 | 0.79 | CES2 (0.50) | CES1CES2SMN1; SMN2RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2128132-B1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME | ADEKA CORP (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-8133656-B2 | Oxime ester compound and photopolymerization initiator containing the same | ADEKA CORPORATION (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133656-B2 | Oxime ester compound and photopolymerization initiator containing the same | ADEKA CORPORATION (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20100075254-A1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME | ADEKA CORPORATION (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20100075254-A1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME | ADEKA CORPORATION (JP) | 2010-03-25 | — | — | US | disclosed |
| EP-2128132-A1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR COMPRISING THE COMPOUND | Adeka Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075254-A1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME | CYP4A11, OXER1, NR2E3 | CES1 474/4885CES2 333/4885SMN1; SMN2 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.